Solid tumor Clinical Trials in Boston, MA

As of July 2026, 114 paid clinical trials are recruiting for Solid tumor in Boston, Massachusetts. Recruiting Solid tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Related specialties in Boston

Oncology· 1,212

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

114 clinical trials for Solid tumor

·Clear filters·↓ Download CSV

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

for Solid Tumor

Drug: Givastomig

3 locations incl. Goodyear

Sponsor: I-Mab Biopharma US Limited

Sex: All·Age: 18+

Code: NCT07432295·Phase 2·Recruiting

Apply to this trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

9 locations incl. New Haven

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07349537·Phase 1·Recruiting

Apply to this trial

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

for Colorectal Cancer

5 locations incl. Boston

Sponsor: PAQ Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07300150·Phase 1·Recruiting

Apply to this trial

A Study of YL242 in Subjects With Advanced Solid Tumors

for Advanced Solid Tumor

7 locations incl. New Haven

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All·Age: 18+

Code: NCT07197827·Phase 1, Phase 2·Recruiting

Apply to this trial

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

7 locations incl. Scottsdale

Sponsor: Tagworks Pharmaceuticals BV

Sex: All·Age: 18+

Code: NCT06959706·Phase 1·Recruiting

Apply to this trial

ARC101 in Advanced Solid Tumors

for Advanced Solid Tumor

3 locations incl. Boston

Sponsor: Third Arc Bio

Sex: All·Age: 18+

Code: NCT06672185·Phase 1·Recruiting

Apply to this trial

Anti-GD2 ADC M3554 in Advanced Solid Tumors

for Advanced Solid Tumor

3 locations incl. Boston

Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All·Age: 18+

Code: NCT06641908·Phase 1·Recruiting

Apply to this trial

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

for Cancer

6 locations incl. Scottsdale

Sponsor: Simcha IL-18, Inc.

Sex: All·Age: 18+

Code: NCT04787042·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

4 locations incl. Boston

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT06167317·Phase 1·Recruiting

Apply to this trial

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

for Advanced Solid Tumor

4 locations incl. Bethesda

Sponsor: Ankyra Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06171750·Phase 1·Recruiting

Apply to this trial

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

for Melanoma

7 locations incl. Aurora

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 17

Code: NCT02332668·Phase 1, Phase 2·Recruiting

Apply to this trial

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

for Locally Advanced Cholangiocarcinoma

4 locations incl. San Francisco

Sponsor: Tyra Biosciences, Inc

Sex: All·Age: 18+

Code: NCT06160752·Phase 1·Recruiting

Apply to this trial

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

for Solid Tumors

6 locations incl. Los Angeles

Sponsor: Apollomics Inc.

Sex: All·Age: 18+

Code: NCT03175224·Phase 2·Recruiting

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

477 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

245 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting

Apply to this trial

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

for Hematopoietic and Lymphatic System Neoplasm

140 locations incl. Birmingham

Sponsor: National Cancer Institute LAO

Sex: All·Age: 2 Months+

Code: NCT02474160·Recruiting

Apply to this trial

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

for Metastatic Malignant Solid Neoplasm

22 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687110·Phase 1·Recruiting

Apply to this trial

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

for Advanced Malignant Solid Neoplasm

27 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06311214·Phase 2·Recruiting

Apply to this trial

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

for Non-small Cell Lung Cancer

20 locations incl. Gilbert

Sponsor: Institut de Recherches Internationales Servier

Sex: All·Age: 18+

Code: NCT05786924·Phase 1, Phase 2·Recruiting

Apply to this trial

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

for Solid Tumor

Drug: Atezolizumab

7 locations incl. Chicago

Sponsor: University of Texas Southwestern Medical Center

Sex: All·Age: 6 Months - 30

Code: NCT04796012·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

51 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting

Apply to this trial

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

for Anatomic Stage III Breast Cancer AJCC v8

Drug: Pidnarulex

2 locations incl. Boston

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07137416·Phase 1·Recruiting

Apply to this trial

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

for Advanced Malignant Solid Neoplasm

Drug: Peposertib

6 locations incl. Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687136·Phase 1·Recruiting

Apply to this trial

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

for Advanced Solid Tumor

1 location in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT06302621·Phase 1·Recruiting

Apply to this trial

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

for Anatomic Stage III Breast Cancer AJCC v8

7 locations incl. Los Angeles

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12+

Code: NCT05372640·Phase 1·Recruiting

Apply to this trial

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

for Wilms Tumor

Drug: Selinexor

16 locations incl. Los Angeles

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 12 Months+

Code: NCT05985161·Phase 2·Recruiting

Apply to this trial

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

for Metastatic Malignant Solid Neoplasm

7 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04585958·Phase 1·Recruiting

Apply to this trial

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

for Esophageal Squamous Cell Carcinoma

10 locations incl. Scottsdale

Sponsor: Plexium, Inc.

Sex: All·Age: 18+

Code: NCT07284186·Phase 1·Recruiting

Apply to this trial

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

for Solid Tumor

11 locations incl. San Francisco

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06952010·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

for Solid Tumors

18 locations incl. Birmingham

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06431594·Phase 1·Recruiting

Apply to this trial

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

for Non-small Cell Lung Cancer

18 locations incl. Duarte

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06218914·Phase 1·Recruiting

Apply to this trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

for Renal Cell Carcinoma (RCC)

46 locations incl. Phoenix

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05176483·Phase 1·Recruiting

Apply to this trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

for Clear Cell Renal Cell Carcinoma

20 locations incl. Birmingham

Sponsor: Arcus Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05536141·Phase 1·Recruiting

Apply to this trial

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

for Solid Tumor

8 locations incl. Aurora

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sex: Female·Age: 18+

Code: NCT04516447·Phase 1·Recruiting

Apply to this trial